Molecular subtype and clinical staging could assist in deciding on therapeutic options for patients with BC [7], for instance, endocrine therapy for Luminal-like BC [8,9], HER2-targeted therapy for HER2-positive BC [10,11], and chemotherapy for TNBC [12,13]. The gene discussed is ERBB2; the disease is breast cancer.